Press coverage about Nevro Corp. (NYSE:NVRO) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nevro Corp. earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.3507463518641 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Nevro Corp. (NVRO) Director Michael F. Demane Sells 5,000 Shares (americanbankingnews.com)
- Nevro Corp. (NVRO) Earns “Buy” Rating from Canaccord Genuity (americanbankingnews.com)
- Judge: Nevro lawyer’s tactic ‘sleazy’ but legal in BSX patent spat – Mass Device (massdevice.com)
- Nevro Corp. (NVRO) Upgraded at BidaskClub (americanbankingnews.com)
- Judge: Nevro lawyer’s tactic ‘sleazy’ but legal in BSX patent spat (massdevice.com)
NVRO has been the subject of a number of research reports. Northland Securities set a $96.00 price objective on shares of Nevro Corp. and gave the stock a “buy” rating in a report on Thursday, June 15th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $102.00 price objective on shares of Nevro Corp. in a report on Monday, July 3rd. Canaccord Genuity reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Nevro Corp. in a report on Wednesday, July 5th. BidaskClub raised shares of Nevro Corp. from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Finally, Zacks Investment Research raised shares of Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 price target for the company in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $101.25.
Nevro Corp. (NYSE NVRO) opened at 92.20 on Wednesday. The stock’s 50 day moving average is $88.43 and its 200 day moving average is $83.72. Nevro Corp. has a one year low of $65.82 and a one year high of $102.26. The firm’s market cap is $2.71 billion.
Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The company had revenue of $78.02 million during the quarter, compared to the consensus estimate of $77.75 million. During the same quarter last year, the company earned ($0.31) earnings per share. The business’s revenue was up 40.8% on a year-over-year basis. On average, equities research analysts expect that Nevro Corp. will post ($1.16) earnings per share for the current year.
In other news, Director Wilfred E. Jaeger sold 79,657 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $82.74, for a total transaction of $6,590,820.18. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $82.31, for a total value of $576,170.00. The disclosure for this sale can be found here. Insiders have sold 290,907 shares of company stock worth $24,670,065 in the last 90 days. Company insiders own 12.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/10/11/nevro-corp-nvro-receives-daily-news-sentiment-rating-of-0-25.html.
Nevro Corp. Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.